News Sanofi faces EU antitrust probe into vaccine business Sanofi has confirmed it is being investigated by the European Commission for potentially anticompetitive activity in its vaccines business.
News FDA clears Novartis' oral drug for chronic hives Novartis has claimed a first-in-class approval in the US for its oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria.
News HHS staffers wait for news after government shutdown The US government has shut down after Republicans and Democrats failed to resolve a budget standoff and the federal government ran out of money.
News Trump, Pfizer announce MFN deal; Lilly, others to come At the White House today, President Trump and Pfizer CEO Albert Bourla announced the first of many deals to secure MFN drug prices for US consumers.
News Data backs Vertanical's cannabis therapy for back pain A phase 3 trial of Vertanical's cannabis extract in back pain has been published, and the results bode well for marketing applications under review.
News New £1.2bn science park opens in Oxford A new £1.2 billion science and technology park was formally opened today in Oxford, in a welcome boost to the UK's life sciences sector.
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.